Connect with us

Featured

Here’s What You Missed “Thanksgiving Edition” (11/21/18)

Daniel Chase

Published

on

stock_price_news

Every year, we sit down to the Thanksgiving table with the same idea; “I’m going to eat as much turkey as I want, but its okay because the L-Tryptophan will help me fall asleep later.” So we set out on our fateful mission, filling our mouths with mashed potatoes, slices of turkey, and green beans, chasing all of it down with a Stein full of gravy. After a valiant effort to eat an amount of food akin to a typical meal for a family of five, you find the nearest cushioned seat or mattress and pass out from your “food coma.” But, is there a real science to the sleepiness we feel from ingesting turkey, and if so, is tryptophan the culprit. 

According to WebMD, the internet’s most trusted source on medicine and human health, turkey contains no more tryptophan than any other kind of poultry. According to Dr. Dawn Blattner, turkey has less tryptophan than chicken. 

Tired yet, well, here’s a special edition of what you missed in the news yesterday, so you have something to read as you fall asleep. 

Well, If That’s How You Really Feel

President Donald Trump announced that the US will stand with Saudi Arabia, despite the fact that the CIA discovered Saudi Crown Prince Mohammed bin Salman ordered the assassination of journalist Jamal Khashoggi. Briefly refreshing your memory, Khashoggi was murdered in the Saudi consulate in Istanbul last month by a 16-person Saudi hit squad. Oh, also his body was totally dismembered. 

No matter the news, President Trump stressed that the US/Saudi Relationship is crucial for keeping the world’s price of crude down. 

“It’s all about, for me, very simple. It’s America first. I’m not going to destroy the world economy and I’m not going to destroy the economy for our country by being foolish with Saudi Arabia.”

President Donald Trump 

Justice Roberts & The Supremes

I know the last piece was about President Trump but, to be fair, his actions typically dominate headlines. 

The president was especially critical of the US federal judges on Wednesday:

“It’s a disgrace when every case gets filed in the 9th circuit. That’s not the law. Every case in the 9th circuit we get beaten and then we end up having to go to the Supreme Court like the travel ban and we won. Every case, no matter where it is, they file is practically, for all intents and purposes, they file it in what’s caked the 9th circuit. This was an Obama judge. I’ll tell you what, it’s not going to happen like this anymore.”

President Donald Trump 

Trump was, of course, responding to the fact that the 9th US Circuit Court of Appeals issued a temporary restraining order on the president’s asylum ban in relation to the thousands of Honduran migrants headed for the US/Mexico border. Because of the separation of powers, the 9th circuit court stepped in to stop President Trump from acting without the consent of Congress and the president did not take too kindly to this obstruction. 

Well, Chief Justice John G. Roberts clapped back at President Trump for his comments:

“I will not cities the political branches. We do that often enough in our opinions. But what I would like to do, briefly, is emphasize how the judicial branch is — how it must be — very different.” 

-Chief Justice John Roberts

Continue Reading
Click to comment

Biotechnology

Biotech Stocks To Watch In June: Cara Therapeutics (CARA) & Intellia Therapeutics (NTLA)

Jon Phillip

Published

on

biotech stocks to watch june

Among biotech companies, the competition between Cara Therapeutics Inc (CARA) and Intellia Therapeutics Inc (NTLA) has been an intriguing one. The two companies had been on the same level as far as the market cap goes during most of the year so far.

But Cara has now pulled ahead by as much as $150 million following positive data from its lead product candidate. That being said, it is also important to keep in mind that if an investor is looking at a long term investment, then the disparity in market cap between the two companies is a minor. Here’s a look at the pros and cons of Cara and Intellia.

Cara Therapeutics (CARA)

Cara Therapeutics is currently on the rise. Its lead product candidate Korsuva injection delivered highly encouraging results in its Phase 3 trial. It’s now believed that it would not be long before Cara has its first product on the market.

[NEXT] Biotech Companies Are Driving Innovation…See Which Ones

It is meant for the treatment of moderate-to-severe chronic kidney disease-associated pruritus. According to reports, the results were great. Another late-stage test is going to be conducted soon. The results could be announced by the end of this year. If Korsuve is approved, then it will be marketed by Fresenius Medical Care and Vifor Pharma Group.

Cara has entered joint ventures with those companies to market the product in the United States, Japan, and South Korea. An oral version of Korsuva is also in the pipeline and could prove to be another important development.

Intellia Therapeutics (NTLA)

Intellia Therapeutics (INTA) is involved in creating CRISPR gene editing therapies. It is a segment that has a lot of promise in the future. Even though the company is some years away from having anything on the market, the promise of gene editing therapy is exciting. So much so that Intellia has already found partners in big-ticket firms like Regeneron and Novartis.

Intellia is expected to file for FDA approval for the clinical study into its lead product NLTA-2001 in 2020. It is meant for the treatment of transthyretin amyloidosis, an uncommon genetic disease. Studies into the products have proven to be promising so far. The company is also working on a product to treat myeloid leukemia.

Now when it comes to choosing between Cara and Intellia, experts believe that the former could a better company. It’s already on the verge of having an approved product on the market. Intellia, on the other hand, is likely to be some years away from winning approval.

Continue Reading

Featured

4 Security Penny Stocks To Watch

A. Lawrence

Published

on

As Threats Arise, Security Stocks Take Center Stage In 2019

With the Federal Reserve’s meeting coming, the general market is bracing for anything. Meanwhile, penny stocks are continuing to climb at absurd rates. Trading penny stocks as of late has brought many investors fruitful profits and they look to continue this trend. Here are some security penny stocks to watch for the remainder of June 2019:

Security Penny Stock #1
Liberty Defense Holdings (SCAN.V)
Market Cap: $46.404M

Liberty Defense Holdings Ltd. (SCAN.V) is a security company looking to take the industry into the next century. Liberty’s HEXWAVE product is a 3-dimensional scanning device that can detect weapons and threats of any kind. The product can do this both with speed and discretion ensuring privacy for citizens.

Liberty signed a Memorandum of Understanding with the soccer team FC Bayern München to beta test HEXWAVE in their arena. They join an ever-growing list of places that have signed MOU’s to beta test Liberty’s product. This MOU expands its ability to comply with and test the market requirements for their product internationally.

“The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America, […] Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.” 

Bill Riker, CEO of Liberty

Security Penny Stock #2
Magal Security Systems (MAGS)
Market Cap: $101.371M

Magal Security Systems Ltd. (MAGS) provides security solutions both online and physical. Some services provided include identifying potential security problems, integrating new systems, and custom designs for any type of security needs.

Recently, Magal received a $5.5 million contract for its advanced perimeter intrusion detection system. The system prevents people from illegally crossing border fences and walls.

Dror Sharon, CEO of Magal, stated, “Magal is a world leader in perimeter intrusion technologies. Our growing wins of orders such as this – providing sensors for active international borders, is due to the decades of experience that we have in providing systems that have more than proven themselves in-the-field.”


Security Penny Stock #3
Rekor Systems (REKR)
Market Cap: $27.502M

Rekor Systems Inc. (REKR) is a company that has developed surveillance technology to enhance public safety, banking, and traffic management. Primarily, the company takes their advanced software, which utilizes machine learning and upgrades IP cameras to the next level. This reduces the cost when collecting highway tolls and helps manage traffic congestion.

REKR stock chart

Throughout June, Rekor Systems has been gaining recognition and application across the US. On June 3rd Rekor obtained a contract to start deploying its Mobile LBR-2 vehicle recognition systems. After this deployment on the 3rd, the LPR-2 system North Carolina law enforcement placed an order. On June 12th, Colorado highway authorities chose Rekor’s cloud system called NUMERUS to read enhance their license plate reading.


Security Penny Stock #4
BIO-key International (BKYI)
Market Cap: $18.03M

BIO-key International Inc. (BKYI) is a security technologies company that is pushing past the limits of fingerprint scanning. BIO-key provides a plethora of finger scanning products that provide security for your computer, hard drive, and the government. They have a partnership with Microsoft to develop biometric sign-in for Windows 10.

The company recently announced that a foreign defense ministry ordered more BIO-key deployment for secure access to Microsoft applications.

“We were delighted that such a capable and prestigious technology team determined that BIO-key met their security and scalability requirements and have now made follow-on investments to grow their user base.  Defense Ministries are constant targets of cyber-attacks, and we are glad to help them step up authentication to the highest assurance with NIST-verified accuracy and FIPS compliance.”

Jim Sullivan, SVP of BIO

security stocks
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Featured

Stock Price Pre Market Update – June 19, 2019

Joe Samuel

Published

on

Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

Click For Full Article


How Tech Is Making Life Easier?

The Answer Is ONE CLICK Away


Healthcare Penny Stocks To Watch

See For Yourself


Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?

You Decide, Click Here

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com